YMAB NASDAQ
Y-mAbs Therapeutics, Inc.
1W: +0.3%
1M: +1.1%
3M: +74.3%
1Y: -35.0%
3Y: -47.2%
5Y: -79.7%
$8.61
Last traded 2025-09-16 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
📊 Key Metrics
TTM$85M
Revenue
-1.3% YoY
$-22M
Net Income
+9.7% YoY
$-18M
Free Cash Flow
-42.8% YoY
86.4%
Gross Margin
-28.7%
Op. Margin
-16.6%
Net Margin
💰 Income Flow
How revenue becomes profit💵 Cash Flow
⚠️ Cash Burn Where cash goes🏦 Balance Sheet
Assets = Liabilities + Equity📈 Financial Health
Profitability
ROE-24.3%
ROA-17.0%
ROIC-74.3%
Valuation
P/E-12.9
P/B4.1
EV/EBITDA-5.8
Leverage
Debt/Equity0.04
Current Ratio4.00
Interest Cov.0.0x
Quality Scores
Piotroski F4/9
Altman Z-1.00
Beneish M-3.01